MEDP Stock Analysis: Buy, Sell, or Hold?
MEDP - Medpace Holdings, Inc. Common Stock
$536.17
5.98 (1.13%)
▲
5d:
-1.85%
30d:
+12.86%
90d:
+6.97%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Jul 22, 2026
7d
Get Alerted When MEDP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: MEDP shows positive signals but monitor for confirmation. Market pricing in 0.7% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: MEDP shows positive signals but monitor for confirmation. Market pricing in 0.7% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$657.46
Based on 6.9% avg growth
INTRINSIC VALUE TODAY
$408.23
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: MEDP is currently trading at $536.17, which is considered slightly high relative to its 30-day fair value range of $464.92 to $540.57. The stock's valuation (Forward PE: 28.4) is in line with its historical norms (27.9). At these levels, the market is pricing in 0.7% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, MEDP is in a downtrend. The price is approaching resistance at $471.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $451.42. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, MEDP is in a downtrend. The price is approaching resistance at $471.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. However, the stock is trading significantly above the average Wall Street target of $451.42. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$464.92 -
$540.57
Company Quality Score
58/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.0%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BEARISH: Trading 15.8% above Wall St target ($451.42)
- NEUTRAL: Market pricing in 0.7% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$464.92 -
$540.57
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
±$37.75
(7.0%)
Support & Resistance Levels
Support Level
$422.00
Resistance Level
$471.23
Current Trend
Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.44
Wall Street Target
$451.42
(-15.8%)
Revenue Growth (YoY)
26.5%
Earnings Growth (YoY)
16.6%
Profit Margin
17.2%
Valuation Premium vs History
+0.7% premium
PE vs Historical
28.4 vs 27.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.7%
(market-implied from PE analysis)
1-Year Target
$539.92
(+1%)
2-Year Target
$543.70
(+1%)
3-Year Target
$547.51
(+2%)
3-Yr Target (if PE normalizes)
(PE: 28→28)
PE COMPRESSION
$537.20
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 28.4, Growth: 9.8%)
$709.64
(+32%)
Base:
(SPY PE: 21.8, Growth: 9.8%)
$543.54
(+1%)
Bear:
(PE: 18.5, Growth: 9.8%)
$462.01
(-14%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (34x PE), but valuation improves significantly next year (28x PE) as earnings recover.
Trailing PE: 33.89 | Current EPS (TTM): $15.88
Bull Case
$702.99
(+31%)
Analyst growth 18.7%, PE expands to 37.3
Base Case
$639.08
(+19%)
Market implied 18.7%, PE stable at 33.9
Bear Case
$366.00
(-32%)
Severe decline -20.0%, PE contracts to 28.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: July 14, 2026 6:40 PM ET
Data refreshes hourly during market hours. Next update: 7:40 PM
Data refreshes hourly during market hours. Next update: 7:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MEDP showing a specific setup today?
Insider Activity (6 Months)
2
Buys
2
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Jesse J Geiger
SELL
31707 shares
2026-03-17
David Taylor
BUY
2026-02-26
David Taylor
BUY
2026-01-29
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$591 | 64 BUY |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$242 | 63 BUY |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$157 | 60 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$271 | 57 HOLD |
Advanced MEDP Option Strategies
Professional options setups generated by AI based on today's MEDP price and gamma walls.
